GRAIL to Present at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum
GRAIL (Nasdaq: GRAL), a healthcare company focused on early cancer detection, has announced its participation in the upcoming Bernstein Insights: Healthcare Leaders and Disruptors – 2nd Annual Healthcare Forum. The company's management will deliver their presentation on Wednesday, September 24, 2025, at 8:00 a.m. ET.
Investors and interested parties can access both the live webcast and replay through GRAIL's investor relations website at investors.grail.com. The presentation recording will remain available for a minimum of 30 days following the event.
GRAIL (Nasdaq: GRAL), azienda sanitaria specializzata nella diagnosi precoce del cancro, parteciperà al prossimo Bernstein Insights: Healthcare Leaders and Disruptors – 2nd Annual Healthcare Forum. La direzione terrà la presentazione mercoledì 24 settembre 2025 alle 8:00 ET.
Investitori e interessati potranno seguire la diretta e la replica sul sito investor relations di GRAIL all'indirizzo investors.grail.com. La registrazione della presentazione sarà disponibile per almeno 30 giorni dopo l'evento.
GRAIL (Nasdaq: GRAL), una compañía sanitaria centrada en la detección temprana del cáncer, ha anunciado su participación en el próximo Bernstein Insights: Healthcare Leaders and Disruptors – 2nd Annual Healthcare Forum. La dirección ofrecerá su presentación el miércoles 24 de septiembre de 2025 a las 8:00 a.m. ET.
Los inversores y otras personas interesadas podrán acceder a la retransmisión en directo y a la repetición a través del sitio de relaciones con inversores de GRAIL en investors.grail.com. La grabación de la presentación estará disponible durante al menos 30 días tras el evento.
GRAIL (Nasdaq: GRAL))은(는) 암 조기 발견에 주력하는 헬스케어 기업으로, 곧 열리는 Bernstein Insights: Healthcare Leaders and Disruptors – 2nd Annual Healthcare Forum에 참가한다고 밝혔습니다. 회사 경영진은 2025년 9월 24일 수요일 오전 8:00 (ET)에 프레젠테이션을 진행합니다.
투자자 및 관심 있는 분들은 GRAIL의 투자자 관계 웹사이트 investors.grail.com을 통해 실시간 웹캐스트와 재생 영상을 시청할 수 있습니다. 프레젠테이션 녹화본은 행사 후 최소 30일 동안 이용 가능합니다.
GRAIL (Nasdaq: GRAL), société de santé spécialisée dans la détection précoce du cancer, a annoncé sa participation au prochain Bernstein Insights: Healthcare Leaders and Disruptors – 2nd Annual Healthcare Forum. La direction présentera son exposé le mercredi 24 septembre 2025 à 8h00 ET.
Les investisseurs et toute personne intéressée pourront accéder au webinaire en direct et au replay via le site relations investisseurs de GRAIL à l'adresse investors.grail.com. L'enregistrement de la présentation restera disponible pendant au moins 30 jours après l'événement.
GRAIL (Nasdaq: GRAL), ein Gesundheitsunternehmen mit Schwerpunkt auf der Früherkennung von Krebs, hat seine Teilnahme am bevorstehenden Bernstein Insights: Healthcare Leaders and Disruptors – 2nd Annual Healthcare Forum angekündigt. Das Management des Unternehmens wird seine Präsentation am Mittwoch, den 24. September 2025, um 8:00 Uhr ET halten.
Investoren und Interessierte können das Live-Webcast und die Aufzeichnung über die Investor-Relations-Website von GRAIL unter investors.grail.com abrufen. Die Aufzeichnung der Präsentation wird für mindestens 30 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in
For more information, visit grail.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-present-at-bernstein-insights-healthcare-leaders-and-disruptors--2nd-annual-healthcare-forum-302552726.html
SOURCE GRAIL, Inc.
FAQ
When is GRAIL (GRAL) presenting at the Bernstein Healthcare Forum 2025?
How can investors access GRAIL's Bernstein Healthcare Forum presentation?
How long will GRAIL's Bernstein Healthcare Forum presentation be available for replay?
What is GRAIL's (GRAL) main business focus?
